Page 28

Marzo_2017

ARTÍCULO DE INVESTIGACIÓN Puntaje de riesgo ACC/AHA 2013 en población chilena - M. Acevedo et al 2. Ministerio de Salud de Chile. Mortalidad por toda causa Chile 2011. http://www.deis.cl/?p=2541; 2011. 3. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97 (18): 1837-47. 4. Icaza G, Núñez L, Marrugat J, Mujica V, Escobar MC, Jiménez AL, et al. Estimación de riesgo de enfermedad coronaria mediante la función de Framingham adaptada para la población chilena. Rev Med Chile 2009; 137 (10): 1273-82. 5. Stone NJ, Robinson JG, Lichtenstein AH, Bairey CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic 298 cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2): S1-45. 6. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet 2013; 382 (9907): 1762-5. 7. Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Amer Coll Cardiol 2014; 64 (10): 959-68. 8. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129 (25 Suppl 2): S49-73. 9. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stats Med 2000; 19 (9): 1141-64. 10. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129 (4): 687-702. 11. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Annals Epidemiol 1991; 1 (3): 263-76. 12. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol 1988; 41 (11): 1105-16. 13. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. An New York Acad Sciences 1963; 107: 539-56. 14. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 1979; 110 (3): 281-90. 15. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stats Med 2004; 23 (13): 2109-23. 16. Lauer MS, Blackstone EH, Young JB, Topol EJ. Cause of death in clinical research: time for a reassessment? J Amer Coll Cardiol 1999; 34 (3): 618-20. 17. Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyeberg EW, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014; 311 (14): 1416-23. 18. Muntner P, Colantonio LD, Cushman M, Goff DC, Howard GH, Horward VJ, et al. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA 2014; 311 (14): 1406-15. Rev Med Chile 2017; 145: 292-298


Marzo_2017
To see the actual publication please follow the link above